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adding this to our public sector guideline in the future, I do
not believe we should add it soon.
South Africa has a massive burden of HIV infection. Adding
WHO stage 3 to the criteria of when to start HAART will
approximately treble the number of eligible patients. Even if
we only targeted stage 4 patients (without using CD4 criteria)
and only managed to treat 50% of these, we would still need
to treat approximately 1 400 000 by 2008 (extrapolated from
ASSA 2002 model by Andrew Boulle). Until it is clear that we
can achieve this daunting target we should not talk about
easing the criteria for initiation. We have an obligation to first
deal with those who are suffering most.
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ANTIRETROVIRAL PROGRAMME RATIONALES
Antiretroviral therapy (ART) programmes are a part of the
response to the massive mortality occurring in the countries
most affected by the HIV epidemic. UNAIDS estimated that 2.3
million deaths from AIDS occurred in sub-Saharan Africa
during 2004. South Africa faces the prospect of an
accumulated 6 - 7 million AIDS deaths by 2010, with the
majority affecting the age group 20 - 40 years, a stage of life
when adults are productive and caring for the next
generation. In September 2003 the World Health Organization
(WHO) declared the lack of access to HIV treatment a global
health emergency. WHO called for ‘unprecedented action’ to
ensure that by the end of 2005 at least 3 million people in
need of ART will have access to it. To date the national
evaluations of the status of ART programmes have revolved
around reporting on numbers on treatment rather than
impact on AIDS mortality. The primary purpose of the South
African and other national ARV programmes is to minimise
HIV-associated mortality.  
DEBATE FOCUS
The key to the present debate revolves around the thresholds
of ART initiation as set out in various treatment guidelines and
how different programme entry criteria impact on population
HIV-related deaths. The WHO Treatment Guidelines Committee
recognises in the 2003 guidelines preface that they will need
to be updated on a regular basis in order to reflect ‘best
current clinical practice’. The SA national rollout programme
currently uses the older WHO 2000 guidelines, which are not
internationally recognised as the ‘best current clinical practice’
and have ceased to be used by many other countries in our
region such as Botswana, Namibia and Uganda.
The current SA guidelines recommend both clinical and CD4
criteria for allowing access to the ART programme. 
APPRAISAL OF PRESENT SA GUIDELINES
Firstly the clinical and CD4 count criteria are very mismatched.
Patients with AIDS die at a rate of 6% per month while
asymptomatic patients with CD4 counts < 200 µl have
approximately a 1% monthly mortality. Clinical AIDS is
therefore very specific for identifying patients at high risk of
death while a CD4 of < 200 is very sensitive measure.
Secondly, the majority of patients access health care and
antiretroviral (ARV) programmes because they have clinical
symptoms rather than because they have just passed the CD4
threshold of < 200 cells. The median CD4 cell count of patients
accessing ARVs in Kampala, Uganda, is still 65/µl and in
Gugulethu, Cape Town, it is less than 100/µl after 3 years of
the programme. A CD4 count of < 200 cells/µl will gain utility
when a large proportion of people living with AIDS (PWAs)
have access to sequential CD4 count monitoring. This CD4
count threshold would then be a very sensitive but not specific
measure for identifying patients at high risk of death.
However, widespread CD4 count testing is not widely available
in South Africa or elsewhere in sub-Saharan Africa. Thirdly, the
clinical threshold of AIDS as an entry criterion for ART results
in high mortality, as there are inevitable delays in accessing
treatment. In Gugulethu the time between referral and
commencing ARVs is short at 28 days. However, 66% of
programme deaths are recorded during this period, occurring
almost exclusively in those patients with AIDS before they
could start ARVs. The reported delay in the Médecins Sans
Frontières, Khayelitsha, ARV project was 4 months. Waiting
time to access ARVs in other programmes is frequently much
longer. Waiting lists in Cape Town hospitals have been up to 8
months and are in excess of 8 months in Malawi, which results
in an unrecorded 50% of AIDS patients dying before access to
ARV programmes. Currently this pre-treatment mortality is
not recorded as part of the treatment programme, although
reduction of HIV mortality is the primary aim of ARV
treatment. AIDS patients not only have a high in-programme
death rate, they are also difficult to clinically manage and
investigate, thereby consuming a disproportionate amount of
programme resources. AIDS is therefore too late a threshold
for entry into an ARV programme. 
If the guidelines do not represent ‘best current clinical
practice’ but are being used as a means of rationing access to
care, they should identify those who will benefit most from
therapy.  Clinical stage is more predictive of HIV mortality than
CD4 count. South African published data have reported that
the death rate of patients with WHO stage 3 disease is 2 - 2.5
times higher than that of asymptomatic patients with < 200
CD4 cells/µl. Until CD4 count testing is more widely available,
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the practical entry into ARV programmes will continue to be
based on presence of clinical symptoms. The only way to
clinically identify patients before AIDS develops is to
encourage programme entry at WHO clinical stage 3.
Extension of ARV treatment protocols to include the
treatment of WHO stage 3 patients will largely access patients
who are already in the health care system and at a time when
their mortality is already approximately 2% per month.  Lastly,
expansion of the clinical criteria for programme access to
stage 3 disease will decrease the numbers of patients
progressing to AIDS in the population and is therefore a more
efficient medium-term strategy.
CONCLUSIONS
Extension of South African Department of Health ARV
treatment guidelines to include the treatment of HIV-
symptomatic patients (i.e. WHO stage 3 and 4) will bring us
into line with all other major national and regional treatment
guidelines.
A CD4 count < 200 cells/µl will only become a practical entry
threshold to ARV programmes when CD4 counts are more
widely available; meanwhile clinical criteria will continue to
define most programme entry. 
The CD4 count of < 200 CD4 cells/µl is a very sensitive but not
specific threshold for identifying those at high risk of death
and therefore greatly increases the potential number of
patients qualifying for the ARV programme. CD4 counts will
become more relevant over time as testing becomes more
widespread.
The present policy of restricting clinical entry to those with
AIDS, results in unacceptably high pre and in-programme
death rates.
In order to achieve the primary aim of the ARV programme, to
minimise deaths of PWA, symptomatic patients (i.e. WHO
stage 3 and 4) should be initially targeted for ART.
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MODERATOR’S SUMMARY
Guidelines for the initiation of antiretroviral treatment have
seen considerable changes over the years.  Initially, we were
persuaded by clinicians in resource-rich settings to ‘hit early,
hit hard ’ – in other words, to commence ARV treatment at
almost any stage of HIV infection.  This was clearly not a
sound option as prolonged therapy with potentially toxic
drugs leads to treatment failure, resistance, cumulative
toxicities and patient treatment fatigue. We were then
persuaded that deferring therapy until certain end-points
were reached was the desirable option. Deferred therapy had
different meanings in the resource-rich and resource-poor
settings. In most guidelines in resource-rich settings
treatment was recommended when patients had an AIDS-
defining condition, CD4 count < 200, stage 3 disease, and in
asymptomatic patients whose CD4 count < 350 and viral load
count was factored in. In resource-poor settings the 2002
WHO guidelines were generally adopted, and these were
embraced by the South African National Programme. These
guidelines advised that treatment should commence for WHO
Stage 4 disease or a CD4 < 200. As Professor Wood pointed
out, waiting for patients to develop stage 4 disease may lead
to an alarming mortality as there are inevitable delays in
accessing treatment while patients are being assessed and
enrolled on programmes.  He also argued that patients should
enter programmes at WHO clinical stage 3. The majority of
these patients are already in the health care system and their
mortality rate is considerably lower.  
Professor Gary Maartens' argument is not totally dissimilar
and he endorses the Southern African HIV Clinicians Society
Guidelines which extend the conservative national guidelines
to include patients with WHO clinical stage 3 disease and a
CD4 count < 350. In asymptomatic patients close monitoring
in the CD4 stratum between 200 and 350 is recommended.
This recommendation is similar to that of the 2003 revision of
the WHO guidelines in which WHO stage 3 disease is added to
the initiation criteria together with a CD4 count of < 350 in
those countries that can measure CD4 counts.
It is sobering to reflect on the scenario that adding WHO stage
3 to the initiation criteria would approximately treble the
number of patients eligible for ARV therapy.  
The ARV guidelines of the Southern African HIV Clinicians
Society were drawn up taking in mind the constrained
resources in our country and do reflect a balance between
need and resources.  It is interesting to note that they are very
similar to the latest version of the WHO clinical guidelines.
Both speakers in this debate have endorsed this as a
reasonable approach for our country in future. 
